THERANOVIR is a young innovative Health-Tech company of Research and Development of breakthrough therapies in 3 fields of closely related pathologies, Cancer, Obesity and associated metabolic diseases and Infectious Diseases by targeting a platform of signaling pathways regulated by the protein complex NRP-1/OBR, newly discovered by the CEO/CSO Dr. Zakia BELAID-SANDAL (PhD). THERANOVIR benefits from a global and exclusive license from INSERM transfert for the valuation of 2 families of granted patents in Europe, United States and Japan. THERANOVIR filed its own patent in January 2023. THERANOVIR is a winner of the Lab-SHAKER 2017 (Genopole), Onco-Entrepreneurs 2018 (Cancer Campus, Villejuif), HEC-Challenge+ 2019 (HEC Paris), Ilab2020 (Ministry of education and research), and Innov'up PIA 2021 (Ile-de-France region) competitions.
Company Details
- Employees
- 3
- Founded
- -
- Address
- Evry, Îledefrance
- Industry
- Biotechnology
- Website
- https://theranovir.com
- Keywords
- #Capital) Dennis Ford ..
- HQ
- Evry, Îledefrance
Theranovir Questions
Theranovir's website is https://theranovir.com
Theranovir's LinkedIn profile is https://fr.linkedin.com/company/theranovir
Theranovir has
3 employees.
View email and phone details for 3
employees at Theranovir.
Theranovir's industry is
Biotechnology
Theranovir's top competitors are
Immunocore,
Skymab Biotherapeutics,
React Therapeutics,
Pepkon,
Ose Immunotherapeutics,
Msinsight,
Bioclonal,
Generare,
Abtx,
Persea.
Theranovir's categories are Biotechnology
Theranovir's founding year is 2018
